000180719 001__ 180719
000180719 005__ 20240229145630.0
000180719 0247_ $$2doi$$a10.1002/alz.12745
000180719 0247_ $$2pmid$$apmid:35852967
000180719 0247_ $$2ISSN$$a1552-5260
000180719 0247_ $$2ISSN$$a1552-5279
000180719 0247_ $$2altmetric$$aaltmetric:132832343
000180719 037__ $$aDKFZ-2022-01510
000180719 041__ $$aEnglish
000180719 082__ $$a610
000180719 1001_ $$aBeyer, Léon$$b0
000180719 245__ $$aAmyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years.
000180719 260__ $$aHoboken, NJ$$bWiley$$c2023
000180719 3367_ $$2DRIVER$$aarticle
000180719 3367_ $$2DataCite$$aOutput Types/Journal article
000180719 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1682517436_25683
000180719 3367_ $$2BibTeX$$aARTICLE
000180719 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180719 3367_ $$00$$2EndNote$$aJournal Article
000180719 500__ $$a#EA:C070# / Volume19, Issue3, March 2023, Pages 1020-1028
000180719 520__ $$aBlood-based biomarkers for Alzheimer's disease (AD) are urgently needed. Here, four plasma biomarkers were measured at baseline in a community-based cohort followed over 17 years, and the association with clinical AD risk was determined.Amyloid beta (Aβ) misfolding status as a structure-based biomarker as well as phosphorylated tau 181 (P-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) concentration levels were determined at baseline in heparin plasma from 68 participants who were diagnosed with AD and 240 controls without dementia diagnosis throughout follow-up.Aβ misfolding exhibited high disease prediction accuracy of AD diagnosis within 17 years. Among the concentration markers, GFAP showed the best performance, followed by NfL and P-tau181. The combination of Aβ misfolding and GFAP increased the accuracy.Aβ misfolding and GFAP showed a strong ability to predict clinical AD risk and may be important early AD risk markers. Aβ misfolding illustrated its potential as a prescreening tool for AD risk stratification in older adults.
000180719 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000180719 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180719 650_7 $$2Other$$aAlzheimer's disease
000180719 650_7 $$2Other$$ablood biomarkers
000180719 650_7 $$2Other$$aimmuno-infrared sensor
000180719 650_7 $$2Other$$arisk stratification
000180719 650_7 $$2Other$$asingle molecule array
000180719 7001_ $$0P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aStocker, Hannah$$b1$$eFirst author$$udkfz
000180719 7001_ $$aRujescu, Dan$$b2
000180719 7001_ $$aHolleczek, Bernd$$b3
000180719 7001_ $$aStockmann, Julia$$b4
000180719 7001_ $$aNabers, Andreas$$b5
000180719 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b6$$udkfz
000180719 7001_ $$aGerwert, Klaus$$b7
000180719 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.12745$$gp. alz.12745$$n3$$p1020-1028$$tAlzheimer's and dementia$$v19$$x1552-5260$$y2023
000180719 909CO $$ooai:inrepo02.dkfz.de:180719$$pVDB
000180719 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000180719 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000180719 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000180719 9141_ $$y2022
000180719 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-28$$wger
000180719 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000180719 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000180719 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000180719 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000180719 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000180719 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000180719 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000180719 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000180719 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000180719 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000180719 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000180719 980__ $$ajournal
000180719 980__ $$aVDB
000180719 980__ $$aI:(DE-He78)C070-20160331
000180719 980__ $$aUNRESTRICTED